Company intelligence / Profile preview

Shanghai Tuoji Biopharmaceutical Technology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Tuoji Biopharma is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule targeted therapies for oncology. The company focuses on addressing unmet medical needs in cancer treatment by targeting key signaling pathways involved in tumor growth and immune evasion. Its lead programs include TJ-M2010, a potent MALT1 inhibitor for B-cell malignancies, and TJ-L101, a KRAS G12C inhibitor for solid tumors. Tuoji Biopharma leverages its internal R&D capabilities to advance a pipeline of precision medicines through early-stage clinical trials.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Tuoji Biopharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Tuoji Biopharmaceutical Technology.

Explore the full profile